Literature DB >> 26566961

Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Harry Alexopoulos1, Angie Biba1, Marinos C Dalakas2.   

Abstract

B cells have an ever-increasing role in the etiopathology of a number of autoimmune neurological disorders, acting as antibody-producing cells and, most importantly, as sensors, coordinators, and regulators of the immune response. B cells, among other functions, regulate the T-cell activation process through their participation in antigen presentation and production of cytokines. The availability of monoclonal antibodies or fusion proteins against B-cell surface molecules or B-cell trophic factors bestows a rational approach for treating autoimmune neurological disorders, even when T cells are the main effector cells. This review summarizes basic aspects of B-cell biology, discusses the role(s) of B cells in neurological autoimmunity, and presents anti-B-cell drugs that are either currently on the market or are expected to be available in the near future for treating neurological autoimmune disorders.

Entities:  

Keywords:  B cells; autoantibodies; autoimmunity; monoclonal antibodies.; neurological disorders; rituximab

Mesh:

Year:  2016        PMID: 26566961      PMCID: PMC4720683          DOI: 10.1007/s13311-015-0402-6

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  153 in total

1.  TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.

Authors:  Claudia Bossen; Teresa G Cachero; Aubry Tardivel; Karine Ingold; Laure Willen; Max Dobles; Martin L Scott; Aris Maquelin; Elodie Belnoue; Claire-Anne Siegrist; Stéphane Chevrier; Hans Acha-Orbea; Helen Leung; Fabienne Mackay; Jürg Tschopp; Pascal Schneider
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

2.  Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.

Authors:  Per S Sorensen; Steen Lisby; Richard Grove; Frederick Derosier; Steve Shackelford; Eva Havrdova; Jelena Drulovic; Massimo Filippi
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

3.  Rituximab use in pediatric central demyelinating disease.

Authors:  Shannon J Beres; Jennifer Graves; Emmanuelle Waubant
Journal:  Pediatr Neurol       Date:  2014-02-15       Impact factor: 3.372

4.  A novel compound heterozygous TACI mutation in an autosomal recessive common variable immunodeficiency (CVID) family.

Authors:  V Lougaris; R Gallizzi; M Vitali; M Baronio; A Salpietro; A Bergbreiter; U Salzer; R Badolato; A Plebani
Journal:  Hum Immunol       Date:  2012-05-22       Impact factor: 2.850

5.  Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG).

Authors:  Y M Huang; P Kivisäkk; V Ozenci; R Pirskanen; H Link
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

6.  Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy.

Authors:  Nagaaki Katoh; Masayuki Matsuda; Wataru Ishii; Hiroshi Morita; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2010-02-01       Impact factor: 1.271

7.  Immunoglobulin-deficient rats fail to develop experimental allergic encephalomyelitis.

Authors:  D O Willenborg; S J Prowse
Journal:  J Neuroimmunol       Date:  1983-10       Impact factor: 3.478

8.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

9.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

10.  APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.

Authors:  M Hahne; T Kataoka; M Schröter; K Hofmann; M Irmler; J L Bodmer; P Schneider; T Bornand; N Holler; L E French; B Sordat; D Rimoldi; J Tschopp
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  11 in total

1.  Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Emerging therapeutic targets for neuromyelitis optica spectrum disorder.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; Alan S Verkman
Journal:  Expert Opin Ther Targets       Date:  2020-03-02       Impact factor: 6.902

Review 3.  Heritable and non-heritable uncommon causes of stroke.

Authors:  A Bersano; M Kraemer; A Burlina; M Mancuso; J Finsterer; S Sacco; C Salvarani; L Caputi; H Chabriat; S Lesnik Oberstein; A Federico; E Tournier Lasserve; D Hunt; M Dichgans; M Arnold; S Debette; H S Markus
Journal:  J Neurol       Date:  2020-04-21       Impact factor: 4.849

Review 4.  Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-02-18       Impact factor: 6.088

Review 5.  Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2018-01-15       Impact factor: 6.570

Review 6.  IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies.

Authors:  Marinos C Dalakas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-29

7.  Bispecific T-Cell Engagers Targeting Membrane-Bound IgE.

Authors:  Aleksandra Rodak; Gerhard Stadlmayr; Katharina Stadlbauer; Dominic Lichtscheidl; Madhusudhan Reddy Bobbili; Florian Rüker; Gordana Wozniak-Knopp
Journal:  Biomedicines       Date:  2021-10-29

8.  Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinical Applications.

Authors:  Giorgio Costagliola; Greta Depietri; Alexandre Michev; Antonella Riva; Thomas Foiadelli; Salvatore Savasta; Alice Bonuccelli; Diego Peroni; Rita Consolini; Gian Luigi Marseglia; Alessandro Orsini; Pasquale Striano
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003

Review 9.  Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.

Authors:  Staley A Brod
Journal:  Mult Scler Relat Disord       Date:  2020-10-07       Impact factor: 4.339

Review 10.  Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects.

Authors:  Marta Waliszewska-Prosół; Justyna Chojdak-Łukasiewicz; Sławomir Budrewicz; Anna Pokryszko-Dragan
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.